We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Efficacy and Safety of Deep Brain Stimulation (DBS) of the Pallidal (GPi) in Patients With Tardive Dystonia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00331669
Recruitment Status : Unknown
Verified February 2009 by Charite University, Berlin, Germany.
Recruitment status was:  Recruiting
First Posted : May 31, 2006
Last Update Posted : March 4, 2009
Information provided by:

Study Description
Brief Summary:
The purpose of this randomized, double blind, multi-center study is to assess the efficacy and safety of bilateral pallidal deep brain stimulation in patients with tardive dystonia.

Condition or disease Intervention/treatment Phase
Dystonia Movement Disorder Procedure: deep brain stimulation Phase 2

Detailed Description:

Deep brain stimulation (DBS) has been established as a new reversible, neurosurgical therapeutic option for patients suffering from disabling neurological movement disorders such as essential tremor and Parkinson´s disease. Recently, deep brain stimulation has been successfully applied in patients with primary generalized and segmental dystonia. Additionally, a number of case reports suggest that pallidal deep brain stimulation may also improve tardive dystonia, which may for instance result from the intake of neuroleptics and which is notoriously difficult to treat medically. The present study will investigate the effects of pallidal DBS using a double blind, randomized design (sham- versus verum-stimulation within a 3-months interval post implantation of the electrodes).

Initially 60 patients had been calculated in a power analysis to assess significant results based on an average improvement of dystonic symptoms of 30%. However, in a recent study (Damier et al., Archives of General Psychiatry, 2007), 10 out of 10 showed a successful outcome of approximately 50% decrease on the extrapyramidal symptoms rating scale score. The exact one- sided lower 95% confidence limit would be 0.794 for this result. If such an approach is chosen for sample size estimation with 18 verum and 18 placebo patients one would obtain a power of 82% against a placebo effect of 30% success rate. For a placebo effect of 25% one needs 16+16 patients and for the placebo effect of 20% one needs 12+12 patients. We thus decided to reduce the sample size to 36- 32- 24 patients. It is expected that the continuous primary outcome measure will preserve even higher power than the binary one used in the study mentioned above. The local ethical committee has approved this.

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Multicenter, Randomized Trial on the Effects of Pallidal Deep Brain Stimulation for Tardive Dystonia
Study Start Date : May 2006
Estimated Study Completion Date : December 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dystonia
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Placebo Comparator: 1
Procedure: deep brain stimulation
high frequency stimulation

Outcome Measures

Primary Outcome Measures :
  1. Improvement of the motor scale of Burke-Fahn-Marsden-Dystonia Rating Scale via blinded video assessment 3 months after starting DBS in comparison to sham-stimulated patients [ Time Frame: 3 months ]

Secondary Outcome Measures :
  1. AIMS [ Time Frame: 3 months ]
  2. Non-motor subscores of BMFDRS [ Time Frame: 3 months ]
  3. Visual analogue scales for both patients and treating physicians [ Time Frame: 3 months ]
  4. Quality of life (SF-36) [ Time Frame: 3 months ]
  5. Psychiatric assessment (HADS-D and PANSS) [ Time Frame: 3 months ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Operational criteria for tardive dystonia for > 18 months after cessation of neuroleptic exposure
  • 18-75 years
  • Relevant functional impairment in daily living activities
  • BFMDRS > 8 or AIMS > 16
  • Informed written consent

Exclusion Criteria:

  • PANNS >60 (Schizophrenia)
  • Hamilton-Score > 18 (Depression)
  • MATTIS-Score <120 (Dementia)
  • Preceding stereotactic neurosurgery
  • Pronounced brain atrophy
  • Increased bleeding risk
  • Decreased immune status
  • Botulinum Toxin treatment within the last 3 months
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00331669

Contact: Andreas R Kupsch, MD, PhD xx49-30-450-50 ext 660103 andreas.kupsch@charite.de
Contact: Andrea Kuehn, MD xx49-30-450-50 ext 660203 andrea.kuehn@charite.de

Andreas Kupsch Recruiting
Berlin, Germany, 13353
Contact: Andreas R Kupsch, MD, PhD    xx49-30-450-50 ext 660103    andreas.kupsch@charite.de   
Contact: Andrea Kuehn, MD    xx49-30-450-50 ext 660203    andrea.kuehn@charite.de   
Principal Investigator: Andreas R Kupsch, MD, PhD         
Sponsors and Collaborators
Charite University, Berlin, Germany
Humboldt-Universität zu Berlin
Ruhr University of Bochum
Medical University of Cologne
Heinrich-Heine University, Duesseldorf
University Hospital Freiburg
Medical University of Hannover
Medical University Innsbruck
University of Kiel
Philipps University Marburg Medical Center
Ludwig-Maximilians - University of Munich
University of Rostock
University of Regensburg
University Hospital Tuebingen
Medical University of Vienna
Principal Investigator: Andreas R Kupsch, MD Dpt. of Neurology, Augustenburger Platz 1, 13353 Berlin, Charite, Campus Virchow, Germany
More Information

ClinicalTrials.gov Identifier: NCT00331669     History of Changes
Other Study ID Numbers: DBS and tardive dystonia
First Posted: May 31, 2006    Key Record Dates
Last Update Posted: March 4, 2009
Last Verified: February 2009

Keywords provided by Charite University, Berlin, Germany:
deep brain stimulation
tardive dystonia
double blind

Additional relevant MeSH terms:
Dystonic Disorders
Movement Disorders
Tardive Dyskinesia
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Central Nervous System Diseases
Dyskinesia, Drug-Induced